Find Latanoprostene Bunod manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

23RELATED EXCIPIENT COMPANIES

44EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Vyzulta, 860005-21-6, Pf-3187207, Bol-303259-x, Ncx 116, Ncx-116
Molecular Formula
C27H41NO8
Molecular Weight
507.6  g/mol
InChI Key
LOVMMUBRQUFEAH-UIEAZXIASA-N
FDA UNII
I6393O0922

Latanoprostene Bunod
Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure. As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Latanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for proposed tissue/cell relaxation effects. In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone. Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost.
1 2D Structure

Latanoprostene Bunod

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
2.1.2 InChI
InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
2.1.3 InChI Key
LOVMMUBRQUFEAH-UIEAZXIASA-N
2.1.4 Canonical SMILES
C1C(C(C(C1O)CC=CCCCC(=O)OCCCCO[N+](=O)[O-])CCC(CCC2=CC=CC=C2)O)O
2.1.5 Isomeric SMILES
C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O
2.2 Other Identifiers
2.2.1 UNII
I6393O0922
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bol 303259-x

2. Bol-303259-x

3. Bol303259-x

4. Ncx 116

5. Ncx-116

6. Ncx116

7. Pf 3187207

8. Pf-3187207

9. Pf3187207

2.3.2 Depositor-Supplied Synonyms

1. Vyzulta

2. 860005-21-6

3. Pf-3187207

4. Bol-303259-x

5. Ncx 116

6. Ncx-116

7. 4-nitrooxybutyl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate

8. I6393o0922

9. 4-(nitrooxy)butyl (5z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((3r)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate

10. Vesneo

11. Latanoprostene Bunod [inn]

12. Unii-i6393o0922

13. Latanoprostene Bunod [usan:inn]

14. Lbn

15. Vyzulta (tn)

16. Lbnncx116

17. Gtpl9635

18. Ncx116

19. Chembl2364612

20. Schembl12119560

21. Latanoprostene Bunod [mi]

22. Chebi:177703

23. Latanoprostene Bunod (usan/inn)

24. Dtxsid101027765

25. Latanoprostene Bunod [usan]

26. Bcp29385

27. Latanoprostene Bunod [who-dd]

28. Db11660

29. Hy-19518

30. Latanoprostene Bunod [orange Book]

31. Cs-0015617

32. D10441

33. Q27280492

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 507.6 g/mol
Molecular Formula C27H41NO8
XLogP34.4
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count18
Exact Mass507.28321727 g/mol
Monoisotopic Mass507.28321727 g/mol
Topological Polar Surface Area142 Ų
Heavy Atom Count36
Formal Charge0
Complexity646
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 1  
Drug NameVYZULTA
Active IngredientLATANOPROSTENE BUNOD
CompanyBAUSCH AND LOMB (Application Number: N207795. Patents: 6211233, 7273946, 7629345, 7910767, 8058467)

4.2 Drug Indication

Latanoprostene bunod opthalmic solution is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Upon applying an appropriate dose of latanoprost bunod, reduction in intraocular pressure begins approximately 1 to 3 hours later with a maximum intraocular pressure reduction effect demonstrated after 11 to 13 hours.


5.2 ATC Code

S - Sensory organs

S01 - Ophthalmologicals

S01E - Antiglaucoma preparations and miotics

S01EE - Prostaglandin analogues

S01EE06 - Latanoprostene bunod


5.3 Absorption, Distribution and Excretion

Absorption

In a study with 22 healthy subjects monitored for 28 days, there were no quantifiable plasma concentrations of latanoprostene bunod (Lower Limit Of Quantitation, LLOQ, of 10.0 pg/mL) or butanediol mononitrate (LLOQ of 200 pg/mL) post daily dose of one drop bilaterally in the morning on Day 1 and 28. The mean time of maximum plasma concentration (Tmax) for latanoprost acid was about 5 minutes post dosage on both Day 1 and 28 of therapy. The mean maximum plasma concentrations (Cmax) of latanoprost acid (LLOQ of 30 pg/mL) were 59.1 pg/mL on Day 1 and 28, respectively.


Route of Elimination

The latanoprost acid component of latanoprostene bunod is predominantly metabolized by the liver and excreted primarily in the urine.


Volume of Distribution

Unfortunately there have been no formal ocular distribution studies performed in humans at this time.


Clearance

Since latanoprost acid plasma concentration dropped below the LLOQ (Lower Limit Of Quantitation) of 30 pg/mL in the majority of study subjects by 15 minutes following ordinary ocular administration, the elimination of latanoprost acid from human plasma is considered rapid.


5.4 Metabolism/Metabolites

Upon topical administration at the ocular surface, latanoprostene bunod undergoes rapid carboxyl ester hydrolysis by endogenous corneal esterases into latanoprost acid and butanediol mononitrate. After the latanoprost acid reaches the systemic circulation, it is largely metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites by way of fatty acid beta-oxidation. The butanediol monohidrate undergoes further metabolism (reduction) to 1,4-butanediol and nitric oxide (NO). Furthermore, this 1,4-butanediol metabolite is further oxidized to succinic acid that is subsequently then primarily taken up as a component in the tricarboxylic acid (TCA) cycle in cellular aerobic respiration.


5.5 Biological Half-Life

The half-life after application of latanoprostene bunod in rabbits was 1.8 hours in cornea, 2.1 hours in aqueous humor, and 4.6 hours in the iris/ciliary body.


5.6 Mechanism of Action

Open-angle glaucoma (OAG) is a medical condition that is associated with progressive visual field damage and the loss of vision. Occular hypertension (OHT) is considered a key risk factor for OAG and reducing intraocular pressure (IOP) and being able to maintain unique and appropriate target IOPs for various different patients having OHT can delay or prevent the onset of primary OAG or slow the disease progression of established glaucoma. Ordinary physiological IOP results from aqueous humor produced by the ocular ciliary body and its outflow through a) the trabecular meshwork (TM) and Schlemm's canal (SC) in what is called the conventional pathway, and b) the uveoscleral pathway via the ciliary muscle/choroid/sclera in what is refered to as the unconventional pathway. In patients with OHT or OAG there is increased resistance to aqueous humor outflow by way of the TM/SC pathway, which causes increased IOP. This increase in IOP is believed to be the cause of mechanical stress on the posterior structures of the eye which can result in the dysfunction of optic nerve fibers and the destruction of retinal ganglion cells - all of which ultimately contributes to vision loss. As there is no cure for glaucoma, therapeutic management is predominantly focused on minimizing disease progression and clinical sequelae via the reduction and maintainenance of appropriate target IOPs. Subsequently, latanoprostene bunod is thought to lower intraocular pressure via a dual mechanism of action since the medication is metabolized into two relevant moieties upon administration: (1) latanoprost acid, and (2) butanediol mononitrate. As a prostaglandin F2-alpha analog, the latanoprost acid moiety operates as a selective PGF2-alpha (FP) receptor agonist. Since FP receptors occur in the ciliary muscle, ciliary epithelium, and sclera the latanoprost acid moiety primarily acts in the uveoscleral pathway where it increases the expression of matrix metalloproteinases (MMPs) like MMP-1, -3, and -9 which promote the degradation of collagen types I, III, and IV in the longitudinal bundles of the ciliary musicle and surrounding sclera. The resultant extracellular matrix remodeling of the ciliary muscle consequently produces reduced outflow resistance via increased permeability and increased aqueous humor outflow through the uveoscleral route. Conversely, the butanediol mononitrate undergoes further metabolism to NO and an inactive 1,4-butanediol moiety. As a gas that can freely diffuse across plasma membranes, it is proposed that the relaxing effect of NO to induce reductions in the cell volume and contractility of vascular smooth muscle like cells is dependant upon activation of the sGC/cGMP/PKG cascade pathway. NO released from butanediol mononitrate consequently enters the cells of the TM and inner wall of SC, causing decreases in myosin light chain-2 phosphorylation, increased phosphorylation of large-conductance calcium-activated potassium (BKCa) channels, and a subsequent efflux of potassium ions through such BKCa channels. All of these changes serve to decrease the cell contractility and volume, as well as to rearrange the actin cytoskeleton of the TM and SC cells. These biomechanical changes ultimately allow for enhanced conventional outflow of aqueous humor.


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChirogate is a professional Prostaglandin manufacturer.

Flag Taiwan
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37976

Submission : 2023-04-24

Status : Active

Type : II

Chirogate CB

02

Cayman Pharma Sro

Czech Republic
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.

Flag Czech Republic
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2024-01-24

Pay. Date : 2023-04-27

DMF Number : 37429

Submission : 2023-05-30

Status : Active

Type : II

Cayman

03

The MedTech Conference
Not Confirmed

03

The MedTech Conference
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39153

Submission : 2023-12-27

Status : Active

Type : II

blank

04

The MedTech Conference
Not Confirmed

04

The MedTech Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-12-16

Pay. Date : 2020-09-30

DMF Number : 34033

Submission : 2019-08-01

Status : Active

Type : II

blank

05

Ys Life Science Co Ltd

Country

USDMF

arrow
The MedTech Conference
Not Confirmed

05

Ys Life Science Co Ltd

Country
arrow
The MedTech Conference
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 40478

Submission : 2024-09-27

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene Bunod IH

Date of Issue : 2022-09-02

Valid Till : 2025-05-05

Written Confirmation Number : WC-0349

Address of the Firm : Unit-II, Sy. No. 50, Kardanur (Village), Patancheru (Mandai), Sangareddy Distric...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-moreread-more

01

Cayman Pharma s.r.o

Czech Republic
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.

Flag Czech Republic
Digital Content Digital Content

Latanoprostene bunode

Registrant Name : Classia Co., Ltd.

Registration Date : 2024-01-15

Registration Number : Su758-10-ND

Manufacturer Name : Cayman Pharma sro

Manufacturer Address : Práce 657, 277 11 Neratovice, Czech Republic

Cayman

02

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene bunode

Registrant Name : Mpeak Korea Co., Ltd.

Registration Date : 2025-02-28

Registration Number : Su812-25-ND

Manufacturer Name : MSN Laboratories Private Lim...

Manufacturer Address : (Unit-ll) Sy. No. 50, 53, 53/A, 54 & 54/A, Kardanur (Village), Patancheru (Mandal), S...

blank

03

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene bunode

Registrant Name : YS Life Science Co., Ltd.

Registration Date : 2024-10-09

Registration Number : 2247-1-ND

Manufacturer Name : YS Life Science Co., Ltd.

Manufacturer Address : 207 Sujeong-ro, Jangan-myeon, Hwaseong-si, Gyeonggi-do

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

LATANOPROSTENE BUNOD

NDC Package Code : 63415-0527

Start Marketing Date : 2019-07-25

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (100kg/100kg)

Marketing Category : BULK INGREDIENT

blank

02

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

LATANOPROSTENE BUNOD

NDC Package Code : 54893-0091

Start Marketing Date : 2019-08-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

LATANOPROSTENE BUNOD

NDC Package Code : 40016-015

Start Marketing Date : 2024-12-17

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

Flag Spain
Digital Content Digital Content

Latanoprostene Bunod

About the Company : With more than 40 years of experience, Gentec Pharmaceutical Group has established itself as one of the leaders in raw materials and ingredients for the food, dietary and nutrition...

With more than 40 years of experience, Gentec Pharmaceutical Group has established itself as one of the leaders in raw materials and ingredients for the food, dietary and nutrition sectors. It manufactures and commercializes more than 200 active pharmaceutical ingredients. It also offers a wide range of finished products. Gentec develops and manufactures services for APIs and intermediates as well as HPAPIs at its Duke Chem and Pharmanoid plants. It also offers a wide range of additional services that cover regulatory and legal matters, such as licenses for the elaboration of product ranges and market assessment.
Gentec Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChirogate is a professional Prostaglandin manufacturer.

Flag Taiwan
Digital Content Digital Content

Latanoprostene Bunod

About the Company : Chirogate, established in 1999, is a leading supplier of niche-market molecules, specializing in prostaglandins. With a focus on quality and compliance, Chirogate has built a reput...

Chirogate, established in 1999, is a leading supplier of niche-market molecules, specializing in prostaglandins. With a focus on quality and compliance, Chirogate has built a reputation as a professional API supplier. Through innovative proprietary processes and advanced technology platforms, Chirogate offers competitively priced prostaglandin products to customers in both regulated and unregulated markets worldwide. Its activities adhere to stringent cGMP regulations and international drug manufacturing codes, guaranteeing the safety and quality of its products. Chirogate has been successfully inspected by regulatory agencies like the USFDA.
Chirogate CB

03

Cayman Pharma s.r.o

Czech Republic
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.

Flag Czech Republic
Digital Content Digital Content

Latanoprostene Bunod

About the Company : Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostagla...

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCentury has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.

Flag India
Digital Content Digital Content

Latanoprostene Bunod

About the Company : Century Pharmaceuticals, established in 1982, has 40 years of experience in manufacturing APIs. It has been supplying APIs produced in-house to several major pharma companies in In...

Century Pharmaceuticals, established in 1982, has 40 years of experience in manufacturing APIs. It has been supplying APIs produced in-house to several major pharma companies in India and abroad. Its APIs are manufactured in accordance with cGMP, 21CFR part 10 and ICH guidelines. It also produces intermediates and develops new APIs as per the needs of its clients. Century conducts biotechnological research that focuses on human therapeutic proteins. Currently, research is underway to find treatments for asthma, mastocytosis and basophilic leukemia. Century supplies research-grade biotech products and a wide range of animal health products.
Century Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

Flag India
Digital Content Digital Content

Latanoprostene Bunod

About the Company : Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical com...

Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical company in 1995. Today, we have 11,000 employees and are heading towards a turnover of INR 50000 million. Our vast network includes 50 C&F agents and 7500+ stockists. We provide a wide range of products – Antibiotic, Antifungal, NSAIDs, Gastrointestinal, Anthelmintic, Cardiovascular, Dermal, Erectile Dysfunction, and several other categories – across the nation.
Company Banner

06

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene Bunod

About the Company : Founded in 1972, and public listed in Taiwan Stock Exchange in 1988, Everlight Chemical focuses on the development of chemical synthesis technology, which gradually became its core...

Founded in 1972, and public listed in Taiwan Stock Exchange in 1988, Everlight Chemical focuses on the development of chemical synthesis technology, which gradually became its core competency. Today the company’s main product lines include: Color Chemicals, Specialty Chemicals, Toner, Electronic Chemicals, Pharmaceutical Chemicals, and Nano-Materials. Having a total of 17 operating locations and 6 production bases around the world, it employs approximately 1,900 employees. In 2017, its revenue approximately was USD300M (NT 9.2 billion).
blank

07

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene Bunod

About the Company : Fleming Laboratories Limited is in the business of manufacturing and supply of high-quality generic Active Pharmaceutical Ingredients (APIs) to the global Pharmaceutical Industry. ...

Fleming Laboratories Limited is in the business of manufacturing and supply of high-quality generic Active Pharmaceutical Ingredients (APIs) to the global Pharmaceutical Industry. The facilities are audited & approved by /accredited with various Regulatory agencies including EUGMP, EDQM, WHO GMP, PMDA (Japan), COFEPRIS (Mexico), Korea FDA.
blank

08

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene Bunod

About the Company : Kimia Biosciences, established in 1993, is focused on manufacturing bulk drugs for various therapeutic segments. With a strong emphasis on excellence and advanced technologies, Kim...

Kimia Biosciences, established in 1993, is focused on manufacturing bulk drugs for various therapeutic segments. With a strong emphasis on excellence and advanced technologies, Kimia aims to become a globally recognized company in both APIs and FDFs while upholding clean business practices. Kimia's state-of-the-art facilities at Village Bhondsi, Gurugram enable it to produce a wide range of APIs. Kimia also plans to establish its own facilities for lifestyle segments, adhering to international regulatory standards. Kimia aims to provide the best pharmaceutical products and support to consumers and healthcare professionals.
blank

09

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene Bunod

About the Company : Founded in 2000, YONSUNG fine chemicals co., Ltd. is a top quality, fast growing manufacturer of APIs, especially, PROSTAGLANDINS and related products for pharmaceutical applicatio...

Founded in 2000, YONSUNG fine chemicals co., Ltd. is a top quality, fast growing manufacturer of APIs, especially, PROSTAGLANDINS and related products for pharmaceutical applications. YONSUNG prides itself on the quality of its products, which gives the company an important competitive edge. The site manufactures API,s for the US, EU and other regulated markets and complies with the cGMP guidelines established by ICH (Q7A). The relevance of new requirements from the FDA, ICH, EMEA and EDQM is continuously monitored.Stringent controls are built-in to ensure that every single product meets the specification of most known pharmacopeias.
blank

10

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene Bunod

About the Company : Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Cente...

Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Center & 1 Mfg. Site which has been certified by US FDA, JPMDA & EMA, supported by >550 highly trained professionals across departments & >200 scientists to bring high quality products to customers. More than 130 products/projects have been successfully developed since founded. Process Innovation, R&D Efficiency & Cost Effectiveness are Ausun's key competencies. Create Chemistry and to be the 1st Class Worldwide Pharmaceutical Corporation is our goal.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649010600,"product":"LATANOPROSTENE BUNOD(QTY:0.002 KGS)","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"DEVA HOLDINGS AS","customerCountry":"TURKEY","quantity":"0.00","actualQuantity":"0.002","unit":"KGS","unitRateFc":"4000000","totalValueFC":"7554.8","currency":"USD","unitRateINR":285000000,"date":"04-Apr-2022","totalValueINR":"570000","totalValueInUsd":"7554.8","indian_port":"HYDERABAD AIR","hs_no":"29397900","bill_no":"9466121","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1654108200,"product":"LATANOPROSTENE BUNOD","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"DEVA HOLDINGS AS","customerCountry":"TURKEY","quantity":"0.07","actualQuantity":"0.071","unit":"KGS","unitRateFc":"2850000","totalValueFC":"198999.5","currency":"USD","unitRateINR":218661971.83098593,"date":"02-Jun-2022","totalValueINR":"15525000","totalValueInUsd":"198999.5","indian_port":"HYDERABAD AIR","hs_no":"29397900","bill_no":"1854591","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1654453800,"product":"LATANOPROSTENE BUNOD(QTY:0.020 KGS)","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"PHARMANEER CO LTD","customerCountry":"TAIWAN","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"2915000","totalValueFC":"57386.2","currency":"USD","unitRateINR":223850000,"date":"06-Jun-2022","totalValueINR":"4477000","totalValueInUsd":"57386.2","indian_port":"HYDERABAD AIR","hs_no":"29397900","bill_no":"1926447","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655145000,"product":"LATANOPROSTENE BUNOD","address":"406,WORLD TRADE CENTRE,SAYAJIGUNJ, ,","city":"VADODARA,GUJARAT","supplier":"CENTURY PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"FUTURE PHARMACEUTICAL INDUSTRIES","customerCountry":"EGYPT","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"2250","totalValueFC":"1974","currency":"USD","unitRateINR":154000,"date":"14-Jun-2022","totalValueINR":"154000","totalValueInUsd":"1974","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"2101972","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"406,WORLD TRADE CENTRE,SAYAJIGUNJ, ,, VADODARA,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1684693800,"product":"MSN PHARMACEUTICAL PRODUCT NAME LATANOPROSTENE BUNOD","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL INCHEON INT","customer":"M PEAK KOREA","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"3000","totalValueFC":"5942.8","currency":"USD","unitRateINR":244500,"date":"22-May-2023","totalValueINR":"489000","totalValueInUsd":"5942.8","indian_port":"HYDERABAD AIR","hs_no":"29375000","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA SOUTH REPUBLIC","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1700505000,"product":"LATANOPROSTENE BUNOD","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"0.00","actualQuantity":"0.001","unit":"KGS","unitRateFc":"5850000","totalValueFC":"4827.6","currency":"USD","unitRateINR":402000000,"date":"21-Nov-2023","totalValueINR":"402000","totalValueInUsd":"4827.6","indian_port":"Hyderabad Air","hs_no":"29375000","bill_no":"5465694","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709231400,"product":"LATANOPROSTENE BUNOD","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"APOTEX INC","customerCountry":"CANADA","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"3040000","totalValueFC":"451410.2","currency":"USD","unitRateINR":249888000,"date":"01-Mar-2024","totalValueINR":"37483200","totalValueInUsd":"451410.2","indian_port":"Hyderabad Air","hs_no":"29375000","bill_no":"7987276","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711132200,"product":"PHARMACEUTICAL RAW MATERIAL - LATANOPROSTENE BUNOD IHS (CAS NO. 860005-21-6)","address":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,","city":"VADODARA GUJ.","supplier":"CENTURY PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"FUTURE PHARMACEUTICAL INDUSTRIES","customerCountry":"EGYPT","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"1600","totalValueFC":"15559.7","currency":"USD","unitRateINR":129200.84,"date":"23-Mar-2024","totalValueINR":"1292008.4","totalValueInUsd":"15559.7","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"8580086","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,, VADODARA GUJ.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1739212200,"product":"LATANOPROSTENE BUNOD","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"MPEAK KOREA CO LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.00","actualQuantity":"4.5","unit":"GMS","unitRateFc":"2350","totalValueFC":"10428.3","currency":"USD","unitRateINR":201530.76222222223,"date":"11-Feb-2025","totalValueINR":"906888.43","totalValueInUsd":"10428.3","indian_port":"Hyderabad Air","hs_no":"29375000","bill_no":"8075358","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1741631400,"product":"PHARMACEUTICATS RAW MATERIAL AS PER INVOICE CPLEXP240O382 LATANOPROSTENE BUNOD BATCH NO. 14140005-LTB","address":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,","city":"VADODARA GUJ.","supplier":"CENTURY PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"TO ORDER","customerCountry":"PAKISTAN","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"2000","totalValueFC":"3866.8","currency":"USD","unitRateINR":167464.5,"date":"11-Mar-2025","totalValueINR":"334929","totalValueInUsd":"3866.8","indian_port":"Bombay Air","hs_no":"29375000","bill_no":"8913268","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,, VADODARA GUJ.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1742927400,"product":"CS-TB-79772 \/ LATANOPROSTENE BUNOD","address":"413 LAXMI MALL LAXMI INDL,","city":"MUMBAI","supplier":"CLEARSYNTH LABS LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"JSC PHARMSTANDARD","customerCountry":"RUSSIA","quantity":"0.00","actualQuantity":"0.5","unit":"GMS","unitRateFc":"735690","totalValueFC":"3959.3","currency":"INR","unitRateINR":685890,"date":"26-Mar-2025","totalValueINR":"342945","totalValueInUsd":"3959.3","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"9382084","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"413 LAXMI MALL LAXMI INDL,, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1753727400,"product":"PHARMACEUTICALS RAW MATERIAL - LATANOPROSTENE BUNOD IHS) (CAS NO. 130209-82-4)","address":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,","city":"VADODARA GUJ.","supplier":"CENTURY PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"TO ORDER","customerCountry":"RUSSIA","quantity":"0.00","actualQuantity":"0.246","unit":"GMS","unitRateFc":"813414.6","totalValueFC":"2315.3","currency":"INR","unitRateINR":810024.71544715448,"date":"29-Jul-2025","totalValueINR":"199266.08","totalValueInUsd":"2315.3","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"3980493","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,, VADODARA GUJ.","customerAddress":""}]
04-Apr-2022
29-Jul-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Vyzulta-Generic (latanoprostene bunod) is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta-Generic

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 01, 2025

blank

01

The Battery Show
Not Confirmed
The Battery Show
Not Confirmed

Details : Vyzulta-Generic (latanoprostene bunod) is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Product Name : Vyzulta-Generic

Product Type : HPAPI

Upfront Cash : Inapplicable

May 01, 2025

blank

Details:

Soleus will acquire Nicox’s VYZULTA royalty, the first nitric oxide donating compound, indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Soleus Capital

Deal Size: $16.5 million Upfront Cash: Undisclosed

Deal Type: Financing October 14, 2024

blank

02

Nicox SA

France
arrow
The Battery Show
Not Confirmed

Nicox SA

France
arrow
The Battery Show
Not Confirmed

Details : Soleus will acquire Nicox’s VYZULTA royalty, the first nitric oxide donating compound, indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.

Product Name : Vyzulta

Product Type : HPAPI

Upfront Cash : Undisclosed

October 14, 2024

blank

Details:

Latanoprostene bunod is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta-Generic

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 23, 2024

blank

03

The Battery Show
Not Confirmed
The Battery Show
Not Confirmed

Details : Latanoprostene bunod is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Product Name : Vyzulta-Generic

Product Type : HPAPI

Upfront Cash : Inapplicable

July 23, 2024

blank

Details:

Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Bausch & Lomb Incorporated

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 23, 2022

blank

04

Nicox SA

France
arrow
The Battery Show
Not Confirmed

Nicox SA

France
arrow
The Battery Show
Not Confirmed

Details : Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Product Name : Vyzulta

Product Type : HPAPI

Upfront Cash : Inapplicable

February 23, 2022

blank

Details:

Under the terms of the exclusive global license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestone payments.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 25, 2021

blank

05

Nicox SA

France
arrow
The Battery Show
Not Confirmed

Nicox SA

France
arrow
The Battery Show
Not Confirmed

Details : Under the terms of the exclusive global license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestone payments.

Product Name : Vyzulta

Product Type : HPAPI

Upfront Cash : Inapplicable

June 25, 2021

blank

Details:

VYZULTA® (latanoprostene bunod ophthalmic solution), is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Nicox SA

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 04, 2021

blank

06

The Battery Show
Not Confirmed
The Battery Show
Not Confirmed

Details : VYZULTA® (latanoprostene bunod ophthalmic solution), is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.

Product Name : Vyzulta

Product Type : HPAPI

Upfront Cash : Inapplicable

May 04, 2021

blank

Details:

VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 22, 2021

blank

07

Nicox SA

France
arrow
The Battery Show
Not Confirmed

Nicox SA

France
arrow
The Battery Show
Not Confirmed

Details : VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.

Product Name : Vyzulta

Product Type : HPAPI

Upfront Cash : Inapplicable

April 22, 2021

blank

Details:

Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Nicox SA

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 16, 2021

blank

08

The Battery Show
Not Confirmed
The Battery Show
Not Confirmed

Details : Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Product Name : Vyzulta

Product Type : HPAPI

Upfront Cash : Inapplicable

March 16, 2021

blank

Details:

Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Nicox SA

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 09, 2021

blank

09

The Battery Show
Not Confirmed
The Battery Show
Not Confirmed

Details : Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Product Name : Vyzulta

Product Type : HPAPI

Upfront Cash : Inapplicable

February 09, 2021

blank

Details:

Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Lead Product(s): Latanoprostene Bunod,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Vyzulta

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Nicox SA

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 22, 2020

blank

10

The Battery Show
Not Confirmed
The Battery Show
Not Confirmed

Details : Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Product Name : Vyzulta

Product Type : HPAPI

Upfront Cash : Inapplicable

December 22, 2020

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

LATANOPROSTENE BUNOD

Brand Name : VYZULTA

Dosage Form : SOLUTION/DROPS;OPHTHALMIC

Dosage Strength : 0.024%

Packaging :

Approval Date : 2017-11-02

Application Number : 207795

Regulatory Info : RX

Registration Country : USA

blank

02

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

LATANOPROSTENE BUNOD

Brand Name : VYZULTA

Dosage Form : SOLUTION

Dosage Strength : 0.024%/W/V

Packaging : 5ML

Approval Date :

Application Number : 2484218

Regulatory Info : Prescription

Registration Country : Canada

blank

03

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene bunod

Brand Name : Vyzulta

Dosage Form : OPD

Dosage Strength : 0,24mg/ml

Packaging : 5X1mg/ml

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank

04

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

LATANOPROSTENE BUNOD

Brand Name : LATANOPROSTENE BUNOD

Dosage Form : SOLUTION/DROPS;OPHTHALMIC

Dosage Strength : 0.024%

Packaging :

Approval Date : 2025-04-29

Application Number : 217387

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

LATANOPROSTENE BUNOD

Brand Name : VYZULTA

Dosage Form : SOLUTION/DROPS;OPHTHALMIC

Dosage Strength : 0.024%

Approval Date : 2017-11-02

Application Number : 207795

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AB

blank

02

GLAND

India
The Battery Show
Not Confirmed
arrow

GLAND

India
arrow
The Battery Show
Not Confirmed

LATANOPROSTENE BUNOD

Brand Name : LATANOPROSTENE BUNOD

Dosage Form : SOLUTION/DROPS;OPHTHALMIC

Dosage Strength : 0.024%

Approval Date : 2025-04-29

Application Number : 217387

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

LATANOPROSTENE BUNOD

Brand Name : VYZULTA

Dosage Form : SOLUTION

Dosage Strength : 0.024%/W/V

Packaging : 5ML

Approval Date :

Application Number : 2484218

Regulatory Info : Prescription

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

South Africa

read-more
read-more

01

The Battery Show
Not Confirmed
arrow
arrow
The Battery Show
Not Confirmed

Latanoprostene bunod

Brand Name : Vyzulta

Dosage Form : OPD

Dosage Strength : 0,24mg/ml

Packaging : 5X1mg/ml

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Topical

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Emulsifying Agents

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 860005-21-6 / Latanoprostene Bunod API manufacturers, exporters & distributors?

Latanoprostene Bunod manufacturers, exporters & distributors 1

24

PharmaCompass offers a list of Latanoprostene Bunod API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Latanoprostene Bunod manufacturer or Latanoprostene Bunod supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Latanoprostene Bunod manufacturer or Latanoprostene Bunod supplier.

PharmaCompass also assists you with knowing the Latanoprostene Bunod API Price utilized in the formulation of products. Latanoprostene Bunod API Price is not always fixed or binding as the Latanoprostene Bunod Price is obtained through a variety of data sources. The Latanoprostene Bunod Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Latanoprostene Bunod

Synonyms

Vyzulta, 860005-21-6, Pf-3187207, Bol-303259-x, Ncx 116, Ncx-116

Cas Number

860005-21-6

Unique Ingredient Identifier (UNII)

I6393O0922

About Latanoprostene Bunod

Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure. As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Latanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for proposed tissue/cell relaxation effects. In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone. Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost.

Latanoprostene Bunod Manufacturers

A Latanoprostene Bunod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Latanoprostene Bunod, including repackagers and relabelers. The FDA regulates Latanoprostene Bunod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Latanoprostene Bunod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Latanoprostene Bunod manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Latanoprostene Bunod Suppliers

A Latanoprostene Bunod supplier is an individual or a company that provides Latanoprostene Bunod active pharmaceutical ingredient (API) or Latanoprostene Bunod finished formulations upon request. The Latanoprostene Bunod suppliers may include Latanoprostene Bunod API manufacturers, exporters, distributors and traders.

click here to find a list of Latanoprostene Bunod suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Latanoprostene Bunod USDMF

A Latanoprostene Bunod DMF (Drug Master File) is a document detailing the whole manufacturing process of Latanoprostene Bunod active pharmaceutical ingredient (API) in detail. Different forms of Latanoprostene Bunod DMFs exist exist since differing nations have different regulations, such as Latanoprostene Bunod USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Latanoprostene Bunod DMF submitted to regulatory agencies in the US is known as a USDMF. Latanoprostene Bunod USDMF includes data on Latanoprostene Bunod's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Latanoprostene Bunod USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Latanoprostene Bunod suppliers with USDMF on PharmaCompass.

Latanoprostene Bunod KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Latanoprostene Bunod Drug Master File in Korea (Latanoprostene Bunod KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Latanoprostene Bunod. The MFDS reviews the Latanoprostene Bunod KDMF as part of the drug registration process and uses the information provided in the Latanoprostene Bunod KDMF to evaluate the safety and efficacy of the drug.

After submitting a Latanoprostene Bunod KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Latanoprostene Bunod API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Latanoprostene Bunod suppliers with KDMF on PharmaCompass.

Latanoprostene Bunod WC

A Latanoprostene Bunod written confirmation (Latanoprostene Bunod WC) is an official document issued by a regulatory agency to a Latanoprostene Bunod manufacturer, verifying that the manufacturing facility of a Latanoprostene Bunod active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Latanoprostene Bunod APIs or Latanoprostene Bunod finished pharmaceutical products to another nation, regulatory agencies frequently require a Latanoprostene Bunod WC (written confirmation) as part of the regulatory process.

click here to find a list of Latanoprostene Bunod suppliers with Written Confirmation (WC) on PharmaCompass.

Latanoprostene Bunod NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Latanoprostene Bunod as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Latanoprostene Bunod API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Latanoprostene Bunod as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Latanoprostene Bunod and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Latanoprostene Bunod NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Latanoprostene Bunod suppliers with NDC on PharmaCompass.

Latanoprostene Bunod GMP

Latanoprostene Bunod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Latanoprostene Bunod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Latanoprostene Bunod GMP manufacturer or Latanoprostene Bunod GMP API supplier for your needs.

Latanoprostene Bunod CoA

A Latanoprostene Bunod CoA (Certificate of Analysis) is a formal document that attests to Latanoprostene Bunod's compliance with Latanoprostene Bunod specifications and serves as a tool for batch-level quality control.

Latanoprostene Bunod CoA mostly includes findings from lab analyses of a specific batch. For each Latanoprostene Bunod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Latanoprostene Bunod may be tested according to a variety of international standards, such as European Pharmacopoeia (Latanoprostene Bunod EP), Latanoprostene Bunod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Latanoprostene Bunod USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty